Compugen Dividends and Buybacks
Dividend criteria checks 0/6
Compugen does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-3.9%
Buyback Yield
| Total Shareholder Yield | -3.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Narrative Update • May 03
CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence
Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.Narrative Update • Apr 07
CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential
Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.Narrative Update • Mar 22
CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings
Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.Narrative Update • Mar 06
CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside
Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
New Narrative • Mar 03
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 20
CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside
Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).Narrative Update • Feb 06
CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside
Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Narrative Update • Jan 23
CGEN: Future Upside Will Be Driven By Royalty Monetization Deal
Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Narrative Update • Jan 09
CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships
Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.Narrative Update • Dec 14
CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program
Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.Analysis Article • Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Analysis Article • Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Narrative Update • Aug 08
AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.Analysis Article • May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...Analysis Article • Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...Analysis Article • Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
New Narrative • Jan 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.Analysis Article • Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...Analysis Article • May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...Analysis Article • May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...Analysis Article • Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...Analysis Article • Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...Analysis Article • Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 12
Compugen appoints Alberto Sessa as CFO
Clinical-stage cancer immunotherapy company Compugen (NASDAQ:CGEN) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. According to CGEN, Sessa has more than 30 years of industry experience and most recently served as acting CFO at several startups in the high-tech industry. CGEN stock flat in mid-day trading.Seeking Alpha • Aug 24
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. CGEN +1.57% to $1.29 premarket Aug. 24Seeking Alpha • Aug 03
Compugen Q2 2022 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.Analysis Article • Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
CEO Anat Cohen-Dayag has done a decent job of delivering relatively good performance at Compugen Ltd. ( NASDAQ:CGEN...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGEN's dividend payments have been increasing.
Dividend Yield vs Market
| Compugen Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CGEN) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (CGEN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate CGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CGEN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CGEN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 00:40 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Compugen Ltd. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |